ArticleTranslational cancer research2025
Efficacy of second- and third-line chemotherapy after chemotherapy with platinum doublet and immunotherapy in non-small cell lung cancer: a descriptive study.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The efficacy of second-line chemotherapy with pemetrexed or docetaxel was evaluated in phase III clinical trials only after prior treatment with a platinum doublet in non-small cell lung cancer. The effectiveness of second-line chemotherapy after previous chemotherapy and immunotherapy is not well known. The effectiveness of third-line chemotherapy is not practically proven in this sense. The aim of this retrospective study was therefore to assess the effectiveness of second- and third-line chemotherapy in patients pretreated with chemotherapy with platinum doublet and immunotherapy based on retrospective data. Methods: Patients from the Czech Lung Cancer Focus (LUCAS) lung cancer registry who were pretreated with chemotherapy and immunotherapy were evaluated. Time on treatment (ToT) and overall survival (OS) with second- and third-line chemotherapy were evaluated using Kaplan-Meier method. Results: One hundred and fourteen patients treated with second-line chemotherapy were evaluated. Their ToT reached a median of 2.9 [95% confidence interval (CI): 2.4-4.7] months and OS a median of 7.2 (95% CI: 6.1-11.2) months. Twenty-two patients treated with third-line chemotherapy were evaluated. Their ToT reached a median of 5.1 (95% CI: 1.4-NA) months and OS a median of 13.8 (95% CI: 6.1-NA) months. Conclusions: The efficacy of second-line chemotherapy in our group of patients (pretreated with chemotherapy and immunotherapy) was comparable with registration studies for second-line chemotherapy. In a selected population, even third-line chemotherapy can be effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.